Linking the IL-17A immune response with NMR-based faecal metabolic profile in IBD patients treated with Mastiha

Amerikanou, Charalampia; Dimitropoulou, Eirini; Gioxari, Aristea; Papada, Efstathia; Tanaini, A.; Fotakis, Charalambos; Zoumpoulakis, Panagiotis; Kaliora, Andriana C.

doi:10.1016/j.biopha.2021.111535

Cited by 11 publications

(7 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, a study by Liu et al [62] showed that miR-155 inhibition TNBS-colitis amelioration was mediated by an impact in the differentiation and function of Th17 cells. The above result come into agreement with our proposed Th17 regulatory role of Mastiha [63].…”

Section: Discussionsupporting

confidence: 92%

“…MiR-155 influences LXR activity and therefore is implicated in the regulation of lipogenic genes, as well as the regulation of Th17 differentiation. Our results parallel with the the Th17 regulatory action in the case of MASTIHA IBD-GR [63] and the lipid regulatory activity Mastiha in the case of MAST4HEALTH [19] under the common key regulators miRNA-155. The above suggested mechanism is presented in Figure 1.…”

Section: Discussionsupporting

confidence: 85%

See 1 more Smart Citation

Mastiha has efficacy in immune-mediated inflammatory diseases through a microRNA-155 Th17 dependent action

Amerikanou

Papada

Gioxari

et al. 2021

Pharmacological Research

Self Cite

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 92%

Section: Discussionsupporting

confidence: 85%

Mastiha has efficacy in immune-mediated inflammatory diseases through a microRNA-155 Th17 dependent action

Amerikanou

Papada

Gioxari

et al. 2021

Pharmacological Research

Self Cite

View full text Add to dashboard Cite

“…Th17 is one type of T helper cell that mainly produces interleukin-17 (IL-17). The IL-17 produced by Th17 cells and innate lymphoid cells has been confirmed to play an important role in IBD (58,59). Recently, researchers found that it also exhibits a crucial function in intestinal fibrosis by contributing to its pathogenesis.…”

Section: T Cellsmentioning

confidence: 99%

Intestinal Fibrosis in Inflammatory Bowel Disease and the Prospects of Mesenchymal Stem Cell Therapy

et al. 2022

View full text Add to dashboard Cite

Intestinal fibrosis is an important complication of inflammatory bowel disease (IBD). In the course of the development of fibrosis, certain parts of the intestine become narrowed, significantly destroying the structure and function of the intestine and affecting the quality of life of patients. Chronic inflammation is an important initiating factor of fibrosis. Unfortunately, the existing anti-inflammatory drugs cannot effectively prevent and alleviate fibrosis, and there is no effective anti-fibrotic drug, which makes surgical treatment the mainstream treatment for intestinal fibrosis and stenosis. Mesenchymal stem cells (MSCs) are capable of tissue regeneration and repair through their self-differentiation, secretion of cytokines, and secretion of extracellular vesicles. MSCs have been shown to play an important therapeutic role in the fibrosis of many organs. However, the role of MSC in intestinal fibrosis largely remained unexplored. This review summarizes the mechanism of intestinal fibrosis, including the role of immune cells, TGF-β, and the gut microbiome and metabolites. Available treatment options for fibrosis, particularly, MSCs are also discussed.

show abstract

“…Since changes in AA levels are considered an early prognostic marker of the disease activity, this indicates a potential role of CMG in remission maintenance. More recently, Amerikanou et al [98] investigated a CMG regulatory effect on IL-a17A serum levels in IBD patients and, as a functional readout of microbial activity, the alterations of the fecal metabolome. In this study, patients with a diagnosis of IBD, 43 UC and 86 CD, either in remission (n = 67) or in relapse (n = 62), were recruited.…”

Section: Effects Of Pistacia Lentiscus On Ibdmentioning

confidence: 99%

Chios Mastic Gum: Chemical Profile and Pharmacological Properties in Inflammatory Bowel Disease: From the Past to the Future

Ottria,

Xynomilakis,

Casati

et al. 2023

IJMS

View full text Add to dashboard Cite

Chios mastic gum, the product of the tree Pistacia lentiscus var. Chia, has been used for more than 2500 years in traditional Greek medicine for treating several diseases, thanks to the anti-inflammatory and antioxidant properties of its components. Despite the long-time use of mastic in gastroenterology and in particular in chronic-inflammation-associated diseases, to date, the literature lacks reviews regarding this topic. The aim of the present work is to summarize available data on the effects of P. lentiscus on inflammatory bowel disease. A comprehensive review of this topic could drive researchers to conduct future studies aimed at deeply investigating P. lentiscus effects and hypothesizing a mechanism of action. The present review, indeed, schematizes the possible bioactive components of mastic gum. Particular care is given to P. lentiscus var. Chia medicaments’ and supplements’ chemical compositions and their pharmacological action in inflammatory bowel disease.

show abstract

Linking the IL-17A immune response with NMR-based faecal metabolic profile in IBD patients treated with Mastiha

Cited by 11 publications

References 46 publications

Mastiha has efficacy in immune-mediated inflammatory diseases through a microRNA-155 Th17 dependent action

Mastiha has efficacy in immune-mediated inflammatory diseases through a microRNA-155 Th17 dependent action

Intestinal Fibrosis in Inflammatory Bowel Disease and the Prospects of Mesenchymal Stem Cell Therapy

Chios Mastic Gum: Chemical Profile and Pharmacological Properties in Inflammatory Bowel Disease: From the Past to the Future

Contact Info

Product

Resources

About